Fertility-sparing surgery for ovarian low malignant potential tumors

Gautam G. Rao, Elizabeth N. Skinner, Paola A. Gehrig, Linda R. Duska, David S. Miller, John O. Schorge

Research output: Contribution to journalArticlepeer-review

50 Scopus citations


Objective. Ovarian low malignant potential (LMP) tumors have an excellent prognosis when treated by surgical resection. Conservative management usually involves leaving behind the uterus and contralateral adnexa to allow future childbearing. The purpose of this study was to determine the outcome of women treated with fertility-sparing surgery. Methods. All patients diagnosed with ovarian LMP tumors between 1984 and 2003 were identified at three institutions. Data were retrospectively extracted from clinical records. Results. Thirty-eight (15%) of 249 women with LMP tumors underwent fertility-sparing surgery. Twenty-three were nulliparous and four primiparous. Thirty-three (87%) underwent unilateral salpingo-ophorectomy and five (13%) cystectomy. Fourteen patients also had contralateral cystectomy or biopsy. Thirty-four (89%) were stage I, one (3%) stage II and three (8%) stage III. Most tumors had serous (55%) or mucinous (42%) histology. No patients received adjuvant therapy. Six (16%) of 38 recurred after a median follow-up of 26 months: five in the remaining ovary were salvaged with surgical resection alone, and none died from recurrent LMP tumor. Five women delivered six term infants during post-treatment surveillance. Conclusion. Fertility-sparing surgery for ovarian LMP tumors is an option for motivated patients. Preservation of the contralateral adnexa increases the risk of recurrence, but surgical resection is usually curative.

Original languageEnglish (US)
Pages (from-to)263-266
Number of pages4
JournalGynecologic oncology
Issue number2
StatePublished - Aug 2005


  • Fertility-sparing surgery
  • Ovarian borderline tumor

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology


Dive into the research topics of 'Fertility-sparing surgery for ovarian low malignant potential tumors'. Together they form a unique fingerprint.

Cite this